Aprea Therapeutics, Inc. (APRE)
SG&A Expense Growth
-13.43%
Quarterly · Period ending:
APRE SG&A Expense Growth
Latest reported-13.43%period ending
Latest reported-13.43%period ending
APRE Quarterly SG&A Growth (QoQ) (0.00% → -13.43%)
Latest values, visible window
High-resolution chart · PNG
APRE sg&a expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expense Growth |
|---|---|
| -13.4346% | |
| 10.7613% | |
| 10.6242% | |
| -7.1126% | |
| -9.706% | |
| 64.5245% | |
| -33.1703% | |
| -13.2688% | |
| -4.096% | |
| 17.4374% | |
| -4.4426% | |
| 1.2364% | |
| -49.5326% | |
| 58.7551% | |
| -31.2201% | |
| -80.2823% | |
| 292.2853% | |
| 18.3802% | |
| -1.4136% | |
| 2.1377% | |
| -2.4084% | |
| -30.0182% | |
| 40.9452% | |
| -8.2832% | |
| 36.3922% | |
| -29.4913% | |
| 70.6177% | |
| 42.59% | |
| 121.9294% | |
| 44.5787% | |
| -19.1202% | |
| 0% |